LBT Innovations (ASX:LBT) Presentation, FNN Investor Event, May 2019, Sydney

Company Presentations

LBT Innovations Limited (ASX:LBT) Managing Director & CEO Brent Barnes presents on LBT's automated plate reading device for use in laboratories, regulatory clearance in the US and the size of the market opportunity at FNN's Investor Event.

Key points:

  • LBT Innovations (ASX:LBT) has an FDA cleared artificial intelligence platform automating manual healthcare processes
  • Commercial launch underway in Australia, Europe and the US
  • 1st sale completed - St. Vincent’s Hospital, Melb
  • FDA cleared - 10,000 patient clinical study
  • Attractive revenue model - upfront + annual fees
  • Cost and efficiency gains for Pathology labs 3 times faster than manual reading
  • Addressable market 2H 2019- 2,000 labs

For more, watch Managing Director & CEO Brent Barnes present.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.